PROFILE OF NEGATIVE DISORDERS IN THE STRUCTURE OF SOCIAL MALADDAPTATION IN PARANOID SCHIZOPHRENIA PATIENTS

Пулатбекова Севара Улугбековна
Магистр 1 года Психиатрия
https://doi.org/10.5281/zenodo.20757394

ARTICLE INFO

Qabul qilindi: 13-iyun 2026 yil
Ma'qullandi: 16- iyun 2026 yil
Nashr qilindi: 19- iyun 2026 yil

KEYWORDS

paranoid schizophrenia, negative symptoms, social maladaptation, avolition, anhedonia, schizophrenia.

ABSTRACT

Paranoid schizophrenia is characterized by a combination of positive (productive) and negative symptoms; however, negative disorders play a leading role in the development of long-term social maladaptation in patients. Negative symptoms include affective flattening, avolition, alogia, anhedonia, and social withdrawal, which significantly reduce the level of social and occupational functioning. The aim of this study is to analyze the profile of negative disorders in patients with paranoid schizophrenia and to assess their contribution to the structure of social maladaptation. It has been demonstrated that the severity of negative symptoms is more strongly associated with impaired social adaptation than positive psychotic symptoms. The obtained data confirm that negative disorders are a key predictor of chronic disability in schizophrenia and require targeted rehabilitation approaches. Early identification and correction of negative symptoms are of particular importance for improving patients' social functioning.

Introduction. Paranoid schizophrenia is one of the most clinically significant and socially burdensome subtypes within the schizophrenia spectrum disorders, characterized by a chronic course, recurrent exacerbations, and a substantial impact on both individual functioning and public health systems. It typically manifests with a predominance of so-called positive (productive) psychotic symptoms, which form the core of the acute clinical picture and often determine initial clinical recognition and hospitalization. The hallmark features of paranoid schizophrenia include systematized delusions, most commonly persecutory delusions, ideas of reference, and delusional misinterpretations of neutral events. These beliefs are typically persistent, poorly amenable to logical correction, and may significantly distort the patient's perception of reality, leading to maladaptive and sometimes behaviorally risky responses. Auditory hallucinations, particularly in the form of "voices" commenting on behavior or engaging in dialogue, are another frequent and clinically important symptom. These hallucinatory experiences are often perceived by patients as externally generated and may contribute to heightened anxiety, suspiciousness, and further reinforcement of delusional systems. In addition to delusions and hallucinations, disturbances in thought processes are also

observed, including loosening of associations, tangentiality, and occasional episodes of disorganized thinking. However, in paranoid schizophrenia, formal thought disorder is generally less prominent than in other subtypes, such as disorganized schizophrenia, which contributes to relatively preserved cognitive structure in some phases of the illness. Despite the prominence of positive symptoms during acute psychotic episodes, paranoid schizophrenia is increasingly understood as a disorder with a broader and more complex psychopathological structure. Over time, the clinical picture is often accompanied by the emergence and persistence of negative symptoms, which play a decisive role in the long-term prognosis and degree of functional impairment. From a social perspective, paranoid schizophrenia is associated with profound disruption of interpersonal relationships, occupational functioning, and overall quality of life. Recurrent psychotic episodes, combined with progressive social withdrawal and cognitive-emotional deficits, contribute to long-term social disability and increased burden on families and healthcare systems. Thus, although positive symptoms define the acute clinical presentation of paranoid schizophrenia, the overall disease trajectory and level of disability are largely determined by the interaction between positive and negative symptom dimensions, as well as their cumulative effect on social adaptation and functional recovery.

However, modern psychiatric research increasingly emphasizes that the long-term outcome of the disorder is determined not only by psychotic (positive) symptoms, but primarily by the persistence and severity of negative symptoms. Negative symptoms in schizophrenia represent a distinct dimension of psychopathology and include affective flattening, alogia, avolition, anhedonia, and social withdrawal. Unlike positive symptoms, which are often episodic and responsive to antipsychotic treatment, negative symptoms tend to be persistent, treatment-resistant, and progressively disabling. They directly affect motivation, emotional responsiveness, and the capacity for goal-directed behavior. From a clinical and social perspective, negative symptoms are considered the principal factor contributing to social maladaptation in patients with paranoid schizophrenia. Social maladaptation is a complex multidimensional construct that reflects the inability of an individual to maintain adequate interpersonal relationships, fulfill occupational roles, and independently manage daily life activities. In this context, patients with pronounced negative symptoms often demonstrate marked deterioration in social functioning, including reduced communication, loss of interest in social interactions, and progressive isolation. Contemporary studies suggest that negative symptoms are more closely associated with functional disability than positive psychotic manifestations. Even in cases where hallucinations and delusions are successfully controlled, patients frequently continue to experience significant impairment in social and occupational functioning due to persistent negative symptoms. This highlights the importance of considering schizophrenia not only as a psychotic disorder but also as a disorder of motivation and social engagement. Despite advances in pharmacological treatment, negative symptoms remain a major therapeutic challenge in psychiatry. Their pathophysiology is complex and involves dopaminergic dysfunction in mesocortical pathways, as well as possible structural and functional brain abnormalities affecting frontal and limbic regions. Moreover, secondary negative symptoms may also arise due to depression, medication side effects, or social deprivation, which further complicates clinical assessment. In forensic psychiatric and rehabilitation contexts, the evaluation of negative symptoms is of particular importance. The

degree of negative symptom severity may influence the assessment of social dangerousness, capacity for self-care, and level of disability. Therefore, a detailed understanding of the structure and profile of negative symptoms is essential for both clinical management and expert evaluation. Given the significant impact of negative symptoms on long-term outcomes, there is a need for systematic analysis of their role in the development of social maladaptation in patients with paranoid schizophrenia. The present study focuses on identifying the predominant components of negative symptomatology and evaluating their contribution to the impairment of social functioning.

Aim of the Study. The aim of this study is to conduct a comprehensive analysis of the profile and structural characteristics of negative symptoms in patients with paranoid schizophrenia, with a particular focus on their clinical variability, predominance, and functional impact. The study seeks to systematically evaluate how specific components of negative symptomatology—such as affective flattening, alogia, avolition, anhedonia, and social withdrawal—are expressed within different stages and clinical forms of paranoid schizophrenia. In addition, the study aims to investigate the role of negative symptoms in the formation and progression of social maladaptation, understood as a multidimensional impairment of interpersonal relationships, occupational performance, and daily living activities. Special attention is given to determining how these symptoms contribute to progressive social isolation and loss of adaptive functioning over time. Another important objective is to establish the relationship between the severity of negative symptomatology and the degree of impairment in social and occupational functioning, using standardized clinical and functional assessment scales. This includes identifying which specific negative symptoms have the strongest predictive value for functional disability and long-term social decline. Furthermore, the study aims to clarify the clinical significance of negative symptoms as a primary determinant of chronic disability in paranoid schizophrenia, distinguishing their impact from that of positive psychotic symptoms. The results are intended to contribute to a better understanding of schizophrenia not only as a psychotic disorder but also as a disorder of motivation, affective expression, and social engagement. Ultimately, the study is oriented toward improving clinical and rehabilitative approaches by highlighting the necessity of early detection, targeted assessment, and symptom-specific intervention strategies aimed at reducing the burden of long-term social dysfunction in patients with paranoid schizophrenia.

Materials and Methods. The study is based on a clinical-psychopathological and functional assessment of patients diagnosed with paranoid schizophrenia according to ICD-10 criteria (F20.0). The sample included patients with a confirmed diagnosis of paranoid schizophrenia with varying duration of illness and stages of disease progression. Clinical evaluation was conducted using standardized psychiatric assessment methods, including structured clinical interviews and observation of mental status. Special attention was paid to the identification and characterization of negative symptoms such as affective flattening, alogia, avolition, anhedonia, and social withdrawal. The severity of psychopathological symptoms was assessed using the Positive and Negative Syndrome Scale (PANSS), with a focus on the negative symptom subscale. Social functioning and level of maladaptation were evaluated using standardized functional assessment tools such as the Global Assessment of Functioning (GAF) scale and the Social Functioning Scale (SFS), which allowed for the quantification of impairments in occupational, interpersonal, and daily living activities. The collected data were

analyzed to determine correlations between the severity of negative symptoms and the degree of social maladaptation. Comparative analysis was performed to evaluate the relative impact of negative and positive symptoms on functional outcomes. Ethical considerations were observed in accordance with the principles of confidentiality and informed consent. The study was conducted in compliance with general requirements for clinical psychiatric research.

Results and Discussion. The analysis of clinical data demonstrated that negative symptoms are a dominant factor in the structure of long-term social maladaptation in patients with paranoid schizophrenia. Across the examined cohort, varying degrees of negative symptom severity were observed, with affective flattening, avolition, and social withdrawal being the most consistently expressed features. Patients with higher scores on the negative symptom subscale of the PANSS showed significantly reduced levels of social and occupational functioning according to the GAF and SFS scales. In particular, avolition and social withdrawal demonstrated the strongest association with impaired daily functioning, including reduced ability to maintain employment, limited participation in social interactions, and decreased self-care motivation. In contrast, positive symptoms such as delusions and hallucinations showed a weaker and less consistent correlation with social maladaptation. In several cases, patients in partial or full remission of positive symptoms continued to exhibit severe functional impairment due to persistent negative symptomatology. This finding supports the concept that clinical remission does not necessarily correspond to functional recovery in paranoid schizophrenia. Affective flattening and alogia were also identified as significant contributors to communication deficits. Patients demonstrated reduced verbal productivity, monotonic speech, and limited emotional expression, which further impaired interpersonal relationships and social integration. Anhedonia was observed as a key factor reducing engagement in recreational and meaningful activities, leading to progressive social isolation. Over time, this pattern contributed to a self-reinforcing cycle of withdrawal, decreased stimulation, and further deterioration of social functioning. The results of the correlation analysis confirmed a strong negative relationship between the severity of negative symptoms and levels of social functioning. This suggests that negative symptomatology is not merely a secondary feature of schizophrenia but a central determinant of long-term disability. From a pathogenetic perspective, these findings are consistent with current neurobiological models implicating dysfunction in the prefrontal cortex and mesocortical dopaminergic pathways in the development of negative symptoms. Additionally, environmental and psychosocial factors, such as prolonged hospitalization and reduced social stimulation, may exacerbate secondary negative symptoms and further worsen social maladaptation. Overall, the results emphasize that negative symptoms represent the core clinical mechanism underlying chronic social disability in paranoid schizophrenia. Their persistence, even in the absence of acute psychotic symptoms, highlights the need for targeted therapeutic and rehabilitation strategies focusing specifically on functional recovery rather than symptom remission alone.

Conclusion. Negative symptoms represent a central and determining component in the clinical structure of paranoid schizophrenia, playing a key role in the development of long-term social maladaptation. The findings of this study demonstrate that affective flattening, avolition, alogia, anhedonia, and social withdrawal are closely associated with significant impairment of social and occupational functioning. It has been shown that the severity of negative symptomatology has a stronger impact on functional disability than positive psychotic

symptoms. Even in cases of clinical stabilization or remission of hallucinations and delusions, persistent negative symptoms continue to limit the patient's ability to achieve adequate social adaptation and independent living. Thus, negative symptoms should be considered a primary target in both therapeutic and rehabilitation strategies for patients with paranoid schizophrenia. Early identification, systematic assessment, and integrated psychosocial interventions are essential for improving long-term outcomes and reducing the level of chronic disability. The results of the study highlight the necessity of shifting clinical focus from symptom control alone to functional recovery-oriented approaches, with special attention to the persistent and disabling nature of negative symptomatology.

References

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Washington (DC): American Psychiatric Association Publishing; 2022.
2. World Health Organization. International statistical classification of diseases and related health problems. 10th revision. Geneva: WHO; 2019.
3. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
4. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry. 1982;39(7):784–788.
5. Carpenter WT Jr, Heinrichs DW, Wagman AMI. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–583.
6. Kirkpatrick B, Fenton WS, Carpenter WT Jr, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–219.
7. Harvey PD, Strassnig MT, Silberstein J. Prediction of disability in schizophrenia: symptoms, cognition, and self-assessment. J Exp Psychopathol. 2019;10(3):204380871986569.
8. Green MF. Impact of cognitive and social cognitive impairment on functional outcomes in schizophrenia. J Clin Psychiatry. 2016;77(2):8–11.
9. Tandon R, Gaebel W, Barch DM, et al. Definition and description of schizophrenia in the DSM-5. Schizophr Res. 2013;150(1):3–10.
10. Buckley PF, Stahl SM. Pharmacological treatment of negative symptoms of schizophrenia: therapeutic opportunity or cul-de-sac? CNS Spectr. 2007;12(S17):1–13.
11. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;5(8):664–677.
12. Foussias G, Remington G. Negative symptoms in schizophrenia: avolition and Occam's razor. Schizophr Bull. 2010;36(2):359–369.
13. Marder SR, Galderisi S. The current conceptualization of negative symptoms in schizophrenia. World Psychiatry. 2017;16(1):14–24.
14. Liddle PF. The symptoms of chronic schizophrenia: a re-examination of the positive-negative dichotomy. Br J Psychiatry. 1987;151:145–151.
15. Barch DM, Ceaser A. Cognition in schizophrenia: core psychological and neural mechanisms. Trends Cogn Sci. 2012;16(1):27–34.
16. Kring AM, Elis O. Emotion deficits in people with schizophrenia. Annu Rev Clin Psychol. 2013;9:409–433.

17. Strauss GP, Cohen AS. A transdiagnostic review of negative symptom phenomenology. Schizophr Bull. 2017;43(4):713–719.
18. Harvey PD, Strassnig MT. Predicting the severity of everyday functional disability in people with schizophrenia. World Psychiatry. 2012;11(2):97–105.
19. Lin CH, Lane HY. Early identification and intervention of schizophrenia: focus on negative symptoms. Adv Exp Med Biol. 2019;1145:127–145.
20. Millan MJ, Fone K, Steckler T, Horan WP. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment. Eur Neuropsychopharmacol. 2014;24(5):645–692.